Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: Report of a large prospective multicenter trial

Blood

Volumn 124, Issue 26, 2014, Pages 3870-3879

  Hoelzer, Dieter ^a,p   Walewski, Jan ^b   Döhner, Hartmut ^c   Viardot, Andreas ^c   Hiddemann, Wolfgang ^d   Spiekermann, Karsten ^d   Serve, Hubert ^a   Dührsen, Ulrich ^e   Hüttmann, Andreas ^e   Thiel, Eckhard ^f   Dengler, Jolanta ^g   Kneba, Michael ^h   Schaich, Markus ⁱ   Schmidt Wolf, Ingo G H ^j   Beck, Joachim ^k   Hertenstein, Bernd ^l   Reichle, Albrecht ^m   Domanska Czyz, Katarzyna ^b   Fietkau, Rainer ⁿ   Horst, Heinz August ^h   Rieder, Harald ^o   Schwartz, Stefan ^f   Burmeister, Thomas ^f   Gökbuget, Nicola ^a   more..

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^j UNIVERSITY OF BONN   (Germany)

^k UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^l General Hospital Bremen Mitte   (Germany)

^m UNIVERSITY HOSPITAL REGENSBURG   (Germany)

ⁿ UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^o UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^p Onkologikum Frankfurt Am Museumsufer   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTITHROMBIN III; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FIBRINOGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; TENIPOSIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CORTICOSTEROID; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLITIS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC INDEX; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; VOMITING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; IMMUNOLOGY; IMMUNOTHERAPY; INTRASPINAL DRUG ADMINISTRATION; LEUKEMIA; MIDDLE AGED; PROCEDURES; PROGNOSIS; REMISSION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; IMMUNOTHERAPY; INJECTIONS, SPINAL; LEUKEMIA; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RITUXIMAB; YOUNG ADULT;

EID: 84919481075     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-563627     Document Type: Article

References (35)

1. Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol. 1986;4(12):1732-1739.
2. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14(3):925-934.
3. Patte C, Philip T, Rodary C, et al. Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol. 1986;4(8):1219-1226.
4. Reiter A, Schrappe M, Ludwig WD, et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood. 1992;80(10):2471-2478.
5. Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87(2):495-508.
6. Diviné M, Casassus P, Koscielny S, et al; GELA; GOELAMS. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol. 2005;16(12):1928-1935.
7. Hoelzer D, Arnold R, Diedrich H, et al. Successful treatment of Burkitt's NHL and other high-grade NHL according to a protocol for mature B-ALL [abstract]. Blood. 2002;100(11). Abstract 595.
8. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17(8):2461-2470.
9. Moleti ML, Testi AM, Giona F, et al. CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience. Leuk Lymphoma. 2007;48(3):551-559.
10. Mead GM, Barrans SL, Qian W, et al; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112(6):2248-2260.
11. Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004;100(7):1438-1448.
12. Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098-1107.
13. Hoelzer D. Novel antibody-based therapies for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:243-249.
14. Costa LJ, Xavier AC, Wahlquist AE, Hill EG. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood. 2013;121(24):4861-4866.
15. Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013;119(20):3672-3679.
16. Wästerlid T, Brown PN, Hagberg O, et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol. 2013;24(7):1879-1886.
17. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361-1392.
18. Cheson BD, Horning SJ, Coiffier B, et al; NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17(4):1244.
19. Hennipman B, de Vries E, Bökkerink JP, Ball LM, Veerman AJ. Intrathecal vincristine: 3 fatal cases and a review of the literature. J Pediatr Hematol Oncol. 2009;31(11):816-819.
20. Rizzieri DA, Johnson JL, Byrd JC, et al; Alliance for Clinical Trials In Oncology (ACTION). Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014;165(1):102-111.
21. Kelly JL, Toothaker SR, Ciminello L, et al. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma. 2009;9(4):307-310.
22. Corazzelli G, Frigeri F, Russo F, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. Br J Haematol. 2012;156(2):234-244.
23. Kasamon YL, Brodsky RA, Borowitz MJ, et al. Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/ leukemia. Leuk Lymphoma. 2013;54(3):483-490.
24. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569-1580.
25. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369(20):1915-1925.
26. Müller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119(14):3276-3284.
27. Pfreundschuh M, Müller C, Zeynalova S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123(5):640-646.
28. Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011;22(8):1859-1864.
29. Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer. 2008;113(1):117-125.
30. Intermesoli T, Rambaldi A, Rossi G, et al. High cure rates in Burkitt lymphoma and leukemia: Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica. 2013;98(11):1718-1725.
31. Mikkelsen TS, Sparreboom A, Cheng C, et al. Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol. 2011;29(13):1771-1778.
32. Poirel HA, Cairo MS, Heerema NA, et al; FAB/LMB 96 International Study Committee. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2009;23(2): 323-331.
33. Mussolin L, Pillon M, Conter V, et al. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood. J Clin Oncol. 2007;25(33):5254-5261.
34. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
35. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.